| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
The molecular function of CD133 in the maintenance of cancer stem cells has not been elucidated. The CD133+ population of Capan-1 pancreatic cancer cell line exhibits cancer stem cell (CSC)-like properties. We established a CD133+ cell-rich subline from Capan-1 cells. Using this subline and the CD133 knocked down cells, we have shown that CD133 facilitates epithelial-mesenchymal transition (EMT) in pancreatic cancer cells. The protein level of EMT regulating transcription factor Slug and the miR-30 family of microRNA level are increased in CD133+ cells, and the expression of these factors can enhance mesenchymal phenotype. In addition, the protein level of HIF-1alpha, which plays a major role in cancer cell survival and aggressiveness in hypoxia, increases in CD133+ cells and may enhance the mesenchymal phenotype.
|
